Bayes Theorem Cystectomy Humans *Laparoscopy Postoperative Complications/surgery *Robotic Surgical Procedures *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Humans Magnetic Resonance Imaging *Multiparametric Magnetic Resonance Imaging Muscles Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/diagnostic imaging Bladder cancer Meta-analysis Muscle invasion Vesical imaging-reporting and data system

Humans Immunotherapy Inflammation Prognosis Progression-Free Survival *Urinary Bladder Neoplasms

Cystectomy/methods Humans Quality of Life *Urinary Bladder Neoplasms/surgery *Urinary Diversion/methods *Urinary Reservoirs Continent nursing systematic review urinary diversion

Female Gene Expression Profiling Gene Regulatory Networks Humans Male Muscles Neoplasm Invasiveness Prognosis *Urinary Bladder Neoplasms/genetics/metabolism rab GTP-Binding Proteins/genetics/metabolism Bladder cancer Gene expression Muscle-invasive bladder cancer Urothelial cancer

Area Under Curve *Carcinoma Transitional Cell Humans In Situ Hybridization Fluorescence ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/pathology Biomarker Cytology Diagnostic Fluorescent in situ hybridization (FISH) Meta-analysis Upper urinary tract urothelial carcinoma (UTUC)

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Humans Female Male Infant *Urinary Bladder Neoplasms/diagnosis/therapy/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Neoplasm Staging Cystoscopy Cystectomy/methods

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

*Carcinoma Renal Cell/complications/epidemiology *Carcinoma Transitional Cell/complications/epidemiology Cross-Sectional Studies Hematuria/epidemiology/etiology Humans Incidence *Kidney Neoplasms/complications/epidemiology Male Prospective Studies Retrospective Studies Risk Factors *Urinary Bladder Neoplasms/complications/epidemiology Age distribution Cystoscopy Haematuria Kidney neoplasms Radiotherapy Sex Smoking Transitional cell carcinoma Urinary bladder neoplasms Urological neoplasms

Humans Female Male *Urinary Bladder Neoplasms/etiology/microbiology RNA Ribosomal 16S/genetics Urinary Bladder/microbiology *Microbiota/genetics Bacteria/genetics Bladder cancer Gender Urinary microbiota Uropathogens of interest.

Artificial Intelligence Humans Muscles/pathology ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnostic imaging/pathology Bladder cancer Meta-analysis Muscle invasive Radiomics Staging Systematic review

Humans *Carcinoma Renal Cell/surgery Prognosis Nutritional Status *Carcinoma Transitional Cell/surgery *Urinary Bladder Neoplasms Nephrectomy *Kidney Neoplasms/surgery Retrospective Studies Controlling Nutritional Status score Renal cell carcinoma Upper tract urothelial carcinoma

Aged Body Mass Index Cohort Studies Female Humans Longitudinal Studies Male Obesity/*complications Risk Factors Urinary Bladder Neoplasms/*etiology/pathology

Cystectomy/*methods Electrosurgery/*methods Humans Neoplasm Invasiveness Urethra Urinary Bladder Neoplasms/pathology/*surgery Bipolar Meta-analysis Monopolar Non-muscle invasive bladder cancer Transurethral resection

Cohort Studies Diet Female Humans Male Prospective Studies Risk Factors Thiamine *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control Vitamin A Vitamin B 12 *Vitamin B Complex B group vitamins Bladder cancer Nutritional oncology Pooled cohort analysis

*Antineoplastic Agents/adverse effects *Carcinoma Transitional Cell/drug therapy Humans Mutation Receptor ErbB-2 Trastuzumab/adverse effects *Urinary Bladder Neoplasms/drug therapy Erbb2 Her2 Metastatic bladder cancer Metastatic urothelial cancer Targeted treatment

Humans Male *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma